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ABSTRACT
Objective. Multimodal analgesia and anal-
gesics with different modes of action can 
reduce perioperative opioid demand and 
their undesirable side effects. 
In our study we presumed that patients 
anesthetised with additional perioperative 
dexmedetomidine infusion, during radi-
cal prostatectomy, would need less opioids 
during and after surgery compared to the 
control group.
Materials and methods. 40 patients, 18-80 
years of age, ASA class 1-3 (American So-
ciety of Anesthesiologists), scheduled for 
radical prostatectomy, were included in 
the study. Patients were randomly divided 
into two groups (20 pts in each group). In 
both groups, fentanyl in repeated boluses 
was used as an analgesic; in the studied 
group, an additional infusion of dexme-
detomidine (0.3 µg/kg/h) was started with 
intravenous line insertion and continued 
until the beginning of wound closure. An-
algesic consumption during the operation, 
in the post-anaesthesia care unit, in the In-
tensive Care Unit on the day of the opera-
tion and on the first postoperative day was 
recorded.
Results. The patients with perioperative 
dexmedetomidine infusion were slightly 
younger (p=0.007), also the duration of 
their surgery was shorter (p =0.05). Differ-
ences in opioid consumption between the 
groups were not found. Also, pain assess-
ment, by visual analogue scale (VAS) after 
12, 18, 24, 30, 36 and 42 hours, was not sta-
tistically different between groups. 
Conclusion. In our study, perioperative 
dexmadetomidine did not reduce peri- 
and postoperative opioid consumption. 
Also, undesirable dexmedetomidine side 
effects, such as bradycardia and hypoten-
sion, were not observed.
Key words: dexmedetomidine, radical pros-
tatectomy 
INTRODUCTION
Radical prostatectomy is one of the exten-
sive urological procedures associated with 
strong postoperative pain and a hormo-
nal and metabolic stress response, which 
can lead to cardiovascular complications, 
increased occurrence of postoperative 
paralytic ileus, weakening of the immune 
response, and changes in carbohydrate and 
protein metabolism. (1) Optimal perio-
perative pain management is therefore 
necessary to inhibit injury triggered pain 
transfer and reduce the autonomous and 
somatic pain response. (2)
For postoperative analgesia, an epidural 
catheter can be used. If there are contrain-
dications or if an epidural catheter cannot 
be inserted, continuous intravenous infu-
sion of piritramide (patient controlled an-
algesia, PCA) can be used. (3,4) Epidural 
analgesia reduces the endocrine and meta-
bolic stress response, facilitates early gut 
mobility, decreases wound infections and 
postoperative respiratory complications. 
(3,5-9)
Given that epidural catheter insertion is an 
invasive method associated with complica-
tions, and that prostatic cancer patients are 
older, often with comorbidites, degenera-
tive spine changes and on anticoagulants, 
this method is often avoided. (10) Only 
opioid based pain relief is associated with 
adverse reactions (insufficient breath-
ing, nausea, vomiting, constipation, ileus, 
drowsiness); also, acute tolerance to opi-
oids may develop intraoperatively. (11-13)
Multimodal analgesia is the most appro-
priate method for postoperative pain relief 
after radical prostatectomy. Pain relief is 
more effective and opioid side effects are 
minimized. (2) Combination of opioids, 
nonopioid analgesics and analgesics with 
a different mode of action, dexmedeto-
midine, reduce opioid consumption and 
their side effects during and after surgery. 
(14- 21)
Dexmedetomidine binds onto α2 adren-
ergic receptors in the locus ceruleus and 
posterior horns of the spinal cord. It also 
inhibits the transfer of pain stimulus and 
reduces the release of norepinephrine. It 
acts simpaticolitically and therefore re-
duces mean arterial pressure and heart 
rate. It also works as an analgesic, hypnotic 
and anxiolytic drug, and does not inhibit 
breathing. (15-18, 22)
Due to the analgesic effect of dexmedeto-
midine, the need for additional opioids is 
reduced, there is less breathing depression, 
nausea and vomiting, bowel function is less 
affected and recovery is faster. (15,19-21)
Dexmedetomidine acts also as an anti-
inflammatory agent. It inhibits the sympa-
thetic nervous system and stimulates the 
parasympathetic nervous system, which 
reduces peripheral proinflammatory cy-
tokine secretion. (23,24,26 )
The aim of our study was to find out if an 
intraoperative dexmedetomidine infusion 
reduces the consumption of opioid analge-




This prospective study included 40 pa-
tients, aged 18 to 80 years, classified ac-
cording to the American Society of An-
aesthesiologists (ASA) into groups 1-3, 
scheduled for radical prostatectomy. 
Prior to the operation, patients gave their 
signed consent for participation in the 
study and for anaesthesia and surgery.  The 
study protocol was approved by the Medi-
cal Ethics Committee of the Republic of 
Slovenia, at the Ministry of Health of the 
Republic of Slovenia (KME 54/07/15).
Patients with allergies to α2 agonists,, un-
controlled arterial hypertension, the pres-
ence of a 2nd or 3rd degree AV block and 
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without signed consent to participate, were 
excluded from the study.
Patients were randomly allocated into two 
groups, depending on the type of analge-
sia during the operation. 20 patients were 
enrolled in each group. During the opera-
tion, patients from both groups received 
fentanyl in repeated doses. Patients in the 
studied group had an intravenous infusion 
of dexmedetomidine started at the time of 
intravenous line insertion until the begin-
ning of surgical wound closure. Consump-
tion of opioids and other analgesics was re-
corded at the end of surgery and on day 1.
Induction of anaesthesia
Aft er the insertion of an intravenous line, 
induction of anaesthesia was performed 
with fentanyl (1-2 µg/kg) and propofol 
(1.5-2.5 mg/kg) or ethomidat (0.2 mg/kg). 
For muscle relaxation rocuronium (0.6 
mg/kg) was used.
Maintenance of anaesthesia
Anaesthesia depth was maintained with 
sevofl urane, depending on the value of the 
bispectral index (BIS, Vista). BIS was kept 
in the range suitable for surgical anaesthe-
sia (40-55). 
Patients were mechanically ventilated (tid-
al volume 6-8 ml/kg). Normothermia and 
normocapnia were maintained. Mean arte-
rial pressure was maintained within ± 25% 
of the basic value. If mean arterial pressure 
decreased more than 25% of basic value, 
vasoactive drugs were used (ephedrine, 
phenylephrine).
Muscle relaxation was measured with TOF 
(train of four). Deep muscle block was 
maintained (TOF 0, posttetanic count, 
PTC 1-2).
Before the operation, patients were ran-
domised into two groups that varied de-
pending on the analgesia. Prior to the sur-
gical incision, patients from both groups 
received an intravenous bolus of fentanyl 
(1-2 µ g/kg). Additional boluses of fen-
tanyl (1-2 µ g/kg) followed according to 
clinical parameters (increase in heart rate 
and blood pressure, sweaty skin, dilated 
pupils). In the studied group, an infusion 
of dexmedetomidine (0.3 µ g/kg/h) was 
started aft er intravenous line insertion and 
stopped at the beginning of wound closure. 
During the operation, fentanyl consump-
tion was recorded. 
According to the measured TOF value at 
the end of the operation, muscle block was 
antagonised with neostigmin (2.5 mg) and 
atropine (1 mg) or sugamadex (2 mg/kg).
4. Postoperative period
At the end of the operation all patients 
received paracetamol (1 g) and an intra-
venous infusion of piritramide with PCA 
(piritramide 0.5 mg/ml, infusion rate 0.5 
mg/h, bolus dose 2 mg, lock out time 30 
minutes). If, in the recovery room or in the 
intensive care unit VAS was ≥ 3, patients 
fi rst received a bolus dose of piritramide 
from PCA and then, if necessary, an addi-
tional bolus of piritramid (3 mg) and par-
acetamol (1 g). Consumption of opioids, 
other analgesics and VAS was evaluated on 
the day of surgery and on the 1st postop-
erative day. VAS was recorded also on the 
2nd postoperative day.
Statistical analysis
Our fi rst aim was to investigate the dif-
ference in general characteristics between 
groups with use of dexmedetomidine and 
without use of dexmedetomidine. Mean 
and standard deviation were used for de-
scription.
Student’s t-test was used to compare varia-
bles with normal distribution (body weight 
and body height) while Mann-Whitney U 
test was used to compare variables that 
were not normally distributed (age, sur-
gery duration, opioid consumption and 
other analgesic consumption). Test of nor-
mality was made for each observed vari-
able. 
Secondly, we investigated the infl uence of 
dexmedetomidine infusion, piritramide 
and paracetamol consumption, surgery 
duration, intraoperative fentanyl use, body 
weight and body height, age, patient ASA 
physical status on VAS aft er 12h with uni-
variate linear regression model.
Finally, we evaluated the infl uence of dex-
medetomidine infusion and postoperative 
piritramide consumption on VAS (visual 
analogue scale) in fi rst 42h, measured eve-
ry 6 hours. Complete information provid-
ed by the longitudinal data was taken into 
account estimating mixed-eff ects regres-
sion models, calculated by Medplot. (25)
Medplot is an application for dynamic 
summary and analysis of longitudinal 
medical data. Th e application uses linear 
regression models for the analysis of nu-
merical outcomes and logistic regression 
models for binary outcomes; a separate 
model is fi tted for each outcome. Th e re-
peated measurements for each subject are 
taken into account using mixed-eff ects re-
gression models.
P value of 0.050 was considered statisti-
cally signifi cant. Values were corrected for 
multiple comparison based on the Holm-
Bonferroni adjustment.
 Power of the study (eff ect size) was calcu-
lated post hoc. For statistical analysis Med-
plot, IBM SPSS Statistics 21 (NY, USA) and 
Gpower (Kiel, Germany) were used.  
RESULTS
Forty patients randomized into two inde-
pendent groups were included in the study. 
In Table 1, ASA health status is presented. 
Th ere was no statistically signifi cant diff er-
ence in ASA health status among the two 
groups (Fisher exact probability test, p= 
0.303, test value 2,390)
Patients’ characteristics and group com-
parison are shown in Table 2. Patients in 
the ttest group with intraoperative dex-
medetomidine infusion were on average 6 
years younger (p=0.007, Mann-Whitney U 
test, test statistic 102,50), surgery duration 
was 16 minutes shorter (p=0.050, Mann-
Whitney U test, test statistic 120,6). Th ere 
was no diff erence in opioid consumption 
among groups.
PAIN ASSESSMENT
Pain assessment (VAS) in the postopera-
tive period is shown in Figure 1.
Variates used in comparison, and their in-
fl uence on VAS aft er 12 hours, are shown 
in Table 3. Pain assessment aft er 12 hours 
was lower in the dexmedetomidine group 
(linear regression model, p = 0.042. See 
statistical analysis for details.).
VAS values in the postoperative period 
(12, 18, 24, 30, 36, 42 hours aft er surgery) 
were analysed in a mixed regression model 
for longitudinal comparison. Th ere was no 
diff erence among groups in general VAS 
assessment in 42 postoperative hours (OR 
1.19 95%CI 0.29-4.87, p=0.809). Higher 
piritramide consumption in recovery was 
related to higher VAS values in the post-
operative period, with a Beta coeffi  cient of 
1.39 (95% CI 1.08 -1.780, p=0.009).
Figure 1. Pain assessment, shown as VAS 
score, in fi rst 42 hours aft er surgery. Aver-
age and 95% confi dence interval are shown. 
VAS, visual analogue scale.
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Table 1. ASA health status of included patients.
Number of patients













total 20 20 40
ASA, American Society of Anaesthesiologists.
Table 2. Patients’ characteristics.
Variable mean (standard deviation)
without Dexmedetomidine
mean (standard deviation) 
Dexmedetomidine group
Age (years) 69.2 (+7.03)* 63 (+7.54)*
Body weight (kg) 84.6 (+6.66) 83.2 (+15.1)
Body height (cm) 174.5 (+5.64) 173.0 (+5.84)
Intraoperative fentanyl consumption (mg) 0.48 (+0.08) 0.48 (+0.09)
Surgery duration time (minutes) 157 (+28)** 141 (+31)**
Piritramide consumption in recovery (mg) 3.37 (+3.27) 2.70 (+2.67)
Paracetamol consumption (g) 1.68 (+0.82) 1.90 (+1.21)
Total piritramide consumption (mg) 31.18 (+13.55) 36.87 (+15.93)
*p = 0.007 (statistically significant p value)
**p = 0.050 
Table 3. Influence of variables on VAS after 12 hours (univariate linear regression, see statistical analysis section for details).
Variable Regression coefficient 95%CI P value
Piritramide consumption 0.006 -0.043 0,055 0.820
Paracetamol consumption 0.753 -0.105 1,611 0.085
Surgery duration -0.009 -0.035 0,016 0.466
Intraoperative fentanyl consumption 0.010 -8.985 9,006 0.998
Patient body weight -0.011 -0.069 0,047 0.709
ASA health status 0.190 -1.259 1,640 0.797
Patient age -0.052 -0.144 0,040 0.268
Patient body height -0.050 -0.183 0.083 0.461
Piritramide consumption in recovery 0.102 -0.124 0.328 0.376
Intraoperative use of dexmedetomidine -1.538 -3.024 0.52 0.042*
* statistically significant p value
ASA, American Society of Anaesthesiologists; VAS, visual analogue scale.
POWER OF THE STUDY
Power of the study was evaluated post hoc. 
Overall piritramide consumption was used 
in the model simulation. For simulation, 
Gaussian distribution of parameter was as-
sumed. Significance of 0.05 and power of 
0.8 were predicted. Calculated effect size 
was d=0.90. Difference among dexmedeto-
midine and test groups in piritramide con-
sumption would be statistically significant 
if average consumption would differ for 
12mg or more. 
DISCUSSION
Forty patients, scheduled for radical pros-
tatic resection, were involved in our clini-
cal randomized prospective study. They 
were randomised into two groups, de-
pending on the type of analgesia received 
during the operation. Intraoperatively, 
both groups received fentanyl in repeated 
doses. In the studied group dexmedetomi-
dine infusion was started after insertion 
of the intravenous line and stopped at the 
beginning of wound closure. At the time 
of study completion, we found out that 
in the dexmedetomidine group patients 
were younger and operation time was 
shorter.  Otherwise, there were no differ-
ences between the two groups in terms of 
body height, body weight and ASA physi-
cal status. During the operation, fentanyl 
consumption was recorded, and after sur-
gery, piritramide consumption was noted. 
We did not find any difference between the 
groups.
So far, few studies have been published 
which monitor intraoperative opioid 
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consumption during simultaneous dex-
medetomidine infusion. As in our study, 
Morgan and colleagues did not find any 
differences in intraoperative opioid con-
sumption during simultaneous dexme-
detomidine infusion (initial bolus 1 µg/
kg, followed by an infusion of 0.5µg/kg/h). 
(26) Also, Dong-Jian Ge did not notice re-
duced intraoperative opioid consumption 
during simultaneous dexmedetomidine 
infusion (0.4 µg/kg/h). (27)
In contrast, reduced intraoperative opioid 
consumption during simultaneous dex-
medetomidine use has been found in both 
laparoscopic and classical bariatric surgery 
and also in laparoscopic and classical hys-
terectomy. (18,21,28,29) In bariatric opera-
tions, Gurbert and Bakhames used a single 
dose of dexmedetomidine (1 µg/kg or 0.8 
µg/kg) for induction in anaesthesia, fol-
lowed by intravenous infusion till the end 
of the operation (0.5 µg/kg/h, or 0.4 µg/
kg/h). (18)
In laparoscopic and classical gynaecologi-
cal operations, MC Queen-Shadfar did not 
find any significant correlation between 
the dose of dexmedetomidine and intra-
operative and postoperative opioid con-
sumption. (28) The same was proven by 
Tufanogullari, who used different doses 
of dexmedetomidine, from 0.2 µg/kg up 
to 0.8 µg/kg. In the same study he demon-
strated a correlation between the dose of 
dexmedetomidine and adverse effects of 
dexmedetomidine on the cardiovascular 
system, such as hypotension, hypertension 
and bradycardia. He, therefore, recom-
mended the smallest dose of dexmedeto-
midine 0.2 µg/kg/h in order to avoid ad-
verse effects. (22)
In our study, we did not use the initial 
single dose of dexmedetomidine. There 
are different opinions regard this topic. 
Some recommend it, because it probably 
prolongs dexmedetomidine analgesic ef-
fect postoperatively. (18,20) With an initial 
dexmedetomidine bolus, efficient dexme-
detomidine plasma concentration can be 
achieved at the beginning of the opera-
tion. Others avoid a bolus of dexmedeto-
midine because of possible side effects. 
(22,28) Ramsay believes that the use of 
the initial bolus will depend on the length 
of anaesthesia. (30) An analgesic effect of 
dexmedetomidine was proven in healthy 
volunteers. (31) Feld and Hofer success-
fully used it in bariatric surgery instead of 
intraoperative opioids. (20,32) In healthy 
volunteers,, a bolus of dexmedetomidine 
had a moderate analgesic effect, in com-
parison to fentanyl, and was found to be 
most effective at a dose of 0.5 µg/kg/h. (33)
In many studies, the influence of intra-
operative dexmedetomidine infusion on 
postoperative opioid and nonopioid an-
algesic consumption has been proven. 
(18- 22,26,27,29,30,34-38) Gubert and 
Arain found better postoperative analge-
sia and 66% lower opioid consumption in 
the first 48 hours after major abdominal 
surgery. In both studies patients received 
a single dose of dexmedetomidine (1 µg/
kg) at induction of anaesthesia, continued 
with intraoperative dexmedetomidine in-
fusion (0.5 µg/kg/h). (18,21,38) Some au-
thors believe that the extended analgesic 
effect of dexmedetomidine, which lasts 
24 to 48 hours after surgery, is a result of 
dexmedetomidine half time, which is 2 to 
3 hours. Others are of the opinion that its 
extended analgesia is due to the anxiolytic 
and thymoleptic properties of  2-agonists, 
which act on an emotional component of 
postoperative pain. (18)
Tufanogullari showed that intraoperative 
dexmedetomidine significantly reduced 
postoperative opioid consumption and 
that it does not depend on the dose of dex-
medetomidine. (22) It is still not proven 
weather a bolus dose of dexmedetomidine 
prolongs postoperative analgesia. (28) 
Bakhames described decreased opioid con-
sumption on the first postoperative day in 
patients, who received an induction bolus 
dose of dexmedetomidine (0.8 µg/kg/h), 
continued by intraoperative infusion (0.4 
µg/kg/h) (21). MC Queen – Shadfar dem-
onstrated reduced postoperative opioid 
consumption only in the recovery room 
after classic, but not after laparoscopic hys-
terectomy, as well. During the operation 
they used a dexmedetomidine infusion 
(0.2 - 1 µg/kg/h), without the bolus dose. 
She concluded that after discharge from re-
covery, opioid consumption in the first 24 
hours after surgery was not decreased. (28) 
Patients operated laparoscopically, needed 
equal doses of opioids as those after classi-
cal surgery. (39)
Patients who received an intraoperative 
dexmedetomidine infusion, needed a first 
bolus of opioid 4 to 6 hours later than pa-
tients from the placebo group, which took 
the first dose of analgesic in the first hours 
after surgery. (26,36)
In our study, we demonstrated a lower 
consumption of opioids during and after 
surgery in a group of patients who received 
an intraoperative dexmedetomine infu-
sion. The cause could be the fact that these 
patients were younger than those in the 
control group. There is evidence that age 
affects the need for analgesics and seda-
tives. (40) But in an analysis of the impact 
of individual factors on VAS after 12 hours, 
we were not able to find the impact of age 
and duration of the operations on the in-
tensity of pain. Biovariability also affects 
pain. Results could be different if all pro-
cedures were to be performed by the same 
surgeon.
In our study, VAS 12 hours after surgery 
in the dexmedetomidine group was sta-
tistically significantly different from the 
control group. The effect was not detected 
in the follow up; it was also too small to 
significantly change the entire load of pain 
in the postoperative period. With a larger 
number of patients in our study or a high-
er-dose of intraoperative dexmedetomi-
dine in the studied group, we might have 
demonstrated the impact of dexmedetomi-
dine on opioid consumption throughout 
the whole postoperative period. Similarly, 
some studies showed that intraoperative 
use of dexmedetomidine did not affect 
the assessment of pain, using VAS, de-
spite the fact that decreased postoperative 
opioid consumption was demonstrated. 
(22,28,38)
CONCLUSIONS
In our study, we demonstrated that in-
traoperative use of dexmedetomidine re-
duces opioid consumption 12 hours after 
surgery. We might be able to reduce opi-
oid consumption even during and after 
surgery, if we included a larger number 
of patients, more homogeneous groups, 
an initial bolus dose of dexmedetomidine 
and/or higher intraoperative dexmedeto-
midine maintenance dose. Side effects of 
dexmedetomidine, such as hypotension 
and bradycardia, were not observed in our 
study.
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